541 results on '"Maurichi, A"'
Search Results
2. One-stage approach to cholecystocholedocholithiasis treatment: a feasible surgical strategy for emergency settings and frail patients
3. BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes
4. Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy
5. Preliminary data on the microbial profile of dry and wet aged bovine meat obtained from different breeds in Sardinia
6. The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086)
7. Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study
8. The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086)
9. Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy
10. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
11. Heme catabolism by tumor-associated macrophages controls metastasis formation
12. Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI)
13. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
14. Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma
15. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer
16. An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells
17. Pigmented spindle-cell nevus: A melanoma simulator
18. Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches
19. Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients
20. One-stage approach to cholecystocholedocholithiasis treatment: a feasible surgical strategy for emergency settings and frail patients
21. Preliminary data on the microbial profile of dry and wet aged bovine meat obtained from different breeds in Sardinia
22. Association of Excision Margin Size With Local Recurrence and Survival in Patients With T1a Melanoma at Critical Structures
23. Potential risk factors, clinicopathological features and determinants of survival for multiple primary melanoma patients compared to single primary melanoma: a large single-center Italian study
24. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup
25. Potential risk factors, clinicopathological features and determinants of survival for multiple primary melanoma patients compared to single primary melanoma: a large single-center Italian study
26. Association of Excision Margin Size With Local Recurrence and Survival in Patients With T1a Melanoma at Critical Structures
27. Supplementary Table 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
28. Supplementary Table 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
29. Supplementary Figure 4 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
30. Supplementary Figure 3 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
31. Supplementary Figure Legend from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
32. Supplementary Figure 5 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
33. Supplementary Data from Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage
34. Supplementary Figures S1, S2, S3, S4, S5 from Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma
35. Data from Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma
36. Supplementary Figure 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
37. Supplementary Figure 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
38. Supplementary Figures 1-10 from Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic Melanoma
39. Similar local recurrence and survival in patients with T1 radial growth phase melanoma on head and neck treated with 5 or 10 mm margins: A retrospective study
40. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
41. Supplementary Figure 5 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
42. Supplementary Figure 3 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
43. Supplementary Figure Legend from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
44. Supplementary Figure 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
45. Data from Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage
46. Supplementary Data from Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage
47. Supplementary Table 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
48. Supplementary Figure 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
49. Supplementary Figure 4 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
50. Data from Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.